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The objective of this study was to evaluate the relationship between self-reported exercise 
levels and Alzheimer’s disease biomarkers, in a cohort of autosomal dominant Alzheimer’s 
disease (ADAD) mutation carriers.  
Methods: 
In 139 pre-symptomatic mutation carriers from the Dominantly Inherited Alzheimer Network, 
the relationship between self-reported exercise levels and brain amyloid load, CSF Aβ42and tau 
levels was evaluated using linear regression.  
Results: 
No differences in brain amyloid load, CSF Aβ42 or tau were observed between low and high 
exercise groups. Nevertheless, when examining only those already accumulating AD pathology 
(i.e. amyloid positive), low exercisers had higher mean levels of brain amyloid than high 
exercisers. Furthermore, the interaction between exercise*estimated years from expected 
symptom onset was a significant predictor of brain amyloid levels. 
Discussion: 
Our findings indicate a relationship exists between self-reported exercise levels and brain 





Deposition of amyloid plaque within the brain contributes to the neuronal and synaptic loss 
consistent with Alzheimer’s disease (AD), while hyperphosphorylation of tau, believed to 
occur downstream of amyloid plaque formation, is associated with AD symptom severity [1]. 
Autosomal dominant AD (ADAD) caused by a mutation in one of three genes: amyloid 
precursor protein (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2), is a rare form of AD 
resulting in alteration of beta-amyloid (Aβ) processing, leading to AD with full penetrance and 
at an early age (typically <50 years). In both sporadic late-onset AD (LOAD) and ADAD, 
accumulation of amyloid manifests up to two decades prior to the presentation of clinical 
symptoms [2, 3], thus, providing a window of opportunity for intervention. However, in both 
LOAD and ADAD there are currently no available pharmaceutical treatments known to alter 
the trajectory of brain amyloid accumulation, nor significantly alter the course of cognitive 
decline.  
Numerous observational studies indicate that high levels of physical activity are associated 
with reduced risk of clinical LOAD [4-7], as well as risk of LOAD mortality [8]. It is likely 
this association is governed by underlying mechanisms, including an effect of physical activity 
on Aβ and/or tau. Indeed, animal studies have demonstrated both soluble and insoluble Aβ 
levels are lowered by exercise in AD transgenic mice [9-15]. Within the small number of 
human studies, greater levels of self-reported physical activity have been associated with lower 
levels of brain amyloid, as measured through amyloid-binding tracers coupled with positron 
emission tomography (PET) [16-18]. Furthermore, Liang and colleagues [16] reported higher 
physical activity levels in older adults were associated with greater levels of cerebrospinal fluid 
(CSF) Aβ42 (an indicator of lower brain amyloid) and lower levels of CSF tau (a marker of 
neuronal injury). The evidence that exercise is associated with lower brain amyloid levels, and 
less neuropathology reflected by CSF Aβ and tau measurements, provides important insight 
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into the possible use of exercise as a therapeutic modality in AD. These associations; however, 
are yet to be examined in individuals with mutations causing ADAD; a gap in knowledge that 
the current study seeks to address.  
The ADAD mutation carriers in the Dominantly Inherited Alzheimer Network (DIAN) study 
[2] provide an excellent model to determine whether exercise is associated with amyloid load, 
as these mutation carriers are destined to accumulate cerebral amyloid at an early age. In the 
current study, we explored relationships between self-reported exercise habits, AD mutation 
carrier status, and AD biomarkers, hypothesising the following among pre-symptomatic 
ADAD mutation carriers: 1) exercise habits are associated with biomarker evidence of Aβ and 
tau (as measured by brain amyloid, CSF Aβ42, and CSF tau), 2) among individuals with 
evidence of brain amyloid, those with higher amounts of exercise would demonstrate less 
evidence of AD biomarkers, and 3) exercise level modifies the relationship between expected 
age of AD symptom onset and AD biomarkers. We also investigated the association between 
exercise and AD neuroimaging and CSF biomarkers, as described above, in mutation non-
carriers included in the DIAN observational study, to evaluate this relationship in those with 







Participants at risk for carrying an ADAD mutation were enrolled in the DIAN study. To be 
eligible for the DIAN study, participants were recruited only if they were a member of a family 
pedigree with known ADAD mutations, with 197 families (from USA, UK and Australia, 
Japan, Germany and Argentina) comprising the DIAN cohort. Information regarding 
participant enrolment and procedures has previously been described in detail [2]. In the current 
cross-sectional analysis, we used baseline data from mutation non-carriers and mutation 
carriers with no cognitive impairment. From DIAN data freeze-10, a total of 435 (mutation 
non-carriers = 172, mutation carriers = 263) participants had baseline data. Individuals with 
missing exercise and PET data, and/or a Clinical Dementia Rating Global score of greater than 
0 were excluded from the analysis (See Figure 1 for full description of participant numbers). 
Participants without available CSF data, but with available PET data, were included in the brain 
amyloid analyses only. All participants underwent a comprehensive clinical assessment 
regarding self and family medical history, medication use, and a physical/medical examination. 
Neuroimaging 
Images obtained through PET with the use of Pittsburgh Compound B (PiB; an Aβ binding 
ligand), were co-registered with individual magnetic resonance images for the identification of 
regions of interest. All studies were collected contemporaneously to baseline determination of 
self-reported exercise. For each region of interest (FreeSurfer defined, MA, USA), a 
standardised uptake value ratio (SUVR) was calculated with the cerebellar cortex used as the 
reference region [19]. The SUVR of the prefrontal cortex, temporal lobe, gyrus rectus and 
precuneus were averaged to calculate a total cortex SUVR. An SUVR of 1·3 was used to 
stratify the cohort based on amyloid positivity (PiB- < 1·3, PiB+ ≥  1·3) [20]. 
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CSF collection and biochemical analyses 
Fasting CSF was collected in the morning via lumbar puncture. Samples were snap frozen and 
shipped on dry ice to the DIAN Biomarker Core laboratory. Levels of Aβ42 and total tau were 
measured by immunoassay (INNO-BIA AlzBio3, Innogenetics, Ghent, Belgium). All values 
included in the analysis met quality control standards, which included; a coefficient of variation 
of 25% or less (typical % CVs were <10%), kit “controls” within the expected range, and 
measurement consistency between plates of a common sample included in each run.  
Genotyping 
For the identification of ADAD genetic mutations in the APP, PSEN1, or PSEN2 genes, 
genotyping was performed on extracted DNA from blood samples. Genotyping was performed 
at The Genome Technology Access Centre at Washington University using the Infinium 
HumanExomeCore V1.0 Beadchip (Illumina, Inc., USA). Genotype data were cleaned by 
applying a minimum call rate for single nucleotide polymorphisms (SNPs) and individuals, set 
at 98%.  
Exercise level evaluation 
Participants reported, via questionnaire, their average time spent partaking in 10 various 
leisure-time exercise activities over the past 12 months in a measurement of ‘minutes per 
week’. This exercise questionnaire has not been previously validated; thus using data available 
from DIAN participants reporting exercise at baseline and at a 1 year follow-up (n = 107), we 
assessed the consistency of exercise reports in this cohort, and report a significant correlation 
with a moderate effect size (r = 0·53, p < 0·0001). Participation in activities such as walking, 
running, cycling, swimming, tennis, aerobics and weight training was recorded. In the 
questionnaire instructions, participants were encouraged to have their responses corroborated 
by their collateral source (e.g. family member or friend). Outliers were minimised by truncation 
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of individual item responses to a maximum of 600 minutes per week (an adaptation of similar 
guidelines regarding maximum reports of daily activities to those recommended for the 
International Physical Activity Questionnaire [21]); this truncation did not alter categorisation 
into the exercise groups (described below). A continuous score was calculated from all items 
by the addition of minutes per week spent exercising in each activity. This continuous score 
was stratified based on current recommendations from the World Health Organisation and the 
American College of Sports Medicine of a minimum of 150 minutes per week of exercise [22, 
23]. Individuals reporting less than 150 minutes of exercise per week were categorised into a 
‘low exercise’ group (mutation non-carriers: n = 37, mutation carriers: n = 33), and those 
participating in more than or equal to 150 minutes of activity per week were categorised into a 
‘high exercise’ group (mutation non-carriers: n = 101, mutation carriers: n = 106). 
Statistical analysis 
Expected years from symptom onset (EYO) was calculated using previously published 
mutation data, if available; if data for a specific mutation was not available then parental age 
of symptom onset was used. The specified age of symptom onset from previously published 
data (or if unavailable, parental age of onset) was taken from the participant’s age at the time 
of assessment to calculate EYO (e.g. a participant aged 30 years at assessment, minus 
previously published age of symptom onset, 37 years: EYO = -7, i.e. 7 years to expected 
symptom onset). Due to the high collinearity between EYO and age (r = 0.79, p < 0.0001), the 
age variable was residualized from EYO for use as a covariate in the linear models. Descriptive 
data was calculated in the form of mean (standard deviation) and percentage (n) for important 
clinical and demographic data. Independent sample t-tests were used to evaluate differences in 
continuous variables, and Chi-square to calculate differences in categorical variables, between 
the low exercise and high exercise groups for both mutation non-carriers and mutation carriers.  
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Following stratification of the study cohort into mutation non-carriers and mutation carriers, a 
series of linear models was used to examine differences in brain amyloid burden and CSF 
biomarker levels between the low exercise and high exercise groups. These analyses were 
conducted in the mutation non-carriers to examine whether associations observed in the 
mutation carriers were unique to this genetic status, or were common to all individuals of a 
similar age group regardless of genetic status. Brain amyloid burden, CSF Aβ and CSF tau 
were entered individually as dependent variables, with exercise group entered as a dichotomous 
independent variable. Furthermore, age (residualized from EYO), family mutation (i.e. APP, 
PSEN1 or PSEN2) and EYO were entered as covariates in all models, with the inclusion of an 
exercise group*EYO interaction. The mutation carrier group was further stratified into those 
who were PiB- versus those who were PiB+, and the models were re-run. The number of 
participants in each group, and stratified groupings, is described in detail in Figure 1. 
All statistical analyses were conducted using the Statistical Package for the Social Sciences 
(IBM SPSS Statistics for Windows, Version 22·0. Armonk, NY: IBM Corp). A p-value of 0·05 
or smaller determined a significant result. False discovery rate (FDR; R environment, version 
3.3.2) was used for group corrections for multiple comparisons [24]. Data were visually 
inspected for outliers and all data-points were within 3.29SD of the mean, a cut-off described 
by Tabachnick and Fidell [25]. Values for individual participants are not displayed on graphs 
(i.e. as a scatter plot) to protect the confidentiality of the mutation status of participants (e.g. 






Descriptive statistics relating to demographics and relevant medical history are detailed in 
Table 1. No differences were observed between the ‘low’ and ‘high’ exercise groups within 
the mutation non-carriers. The mutation carrier ‘low exercise’ group (38·6 ± 7·9 years) was 
significantly older than the mutation carrier ‘high exercise’ group (33·7 ± 9·3 years; t = 2·68, 
p = 0·008). Depressive symptoms (as measured by the geriatric depression scale; GDS) were 
significantly higher among the mutation carrier ‘low exercise’ group (2·2 points ± 2·2 points) 
compared to the mutation carrier ‘high exercise’ group (1·4 points ± 1·8 points; t = 2·04, p = 
0·04). To evaluate the effect of depressive symptoms on the relationship between exercise and 
AD neuroimaging and CSF biomarkers, GDS was entered as a covariate into the models 
reported in Table 2; however, the inclusion of GDS did not alter the findings (data not reported), 
and thus this variable was not included in the final analysis. 
The impact of exercise on Aβ and tau 
Within the mutation non-carriers (Table 2), no differences in PiB SUVR (F = 0·33, p = 0·60), 
CSF Aβ42 (F = 1.48, p = 0·23) and CSF tau (F = 2·26, p = 0·14) were evident between the ‘low 
exercise’ and ‘high exercise’ groups. On examination of all mutation carriers (Table 3), there 
were also no differences in PiB SUVR (F = 2.68, p = 0.10), CSF Aβ42 (F = 0.01, p = 0.95) and 
CSF tau levels (F = 0.25, p  = 0.62) between the ‘low exercise’ and ‘high exercise’ groups. In 
order to examine only those individuals in whom significant brain amyloid load was already 
present, we stratified the mutation carriers based on PiB positivity (cut-off: 1·3), and re-ran the 
linear models. In the PiB+ group, lower brain amyloid burden was observed in the MC ‘high 
exercisers’ (SUVR: 2·16 ± 0·15) compared with the mutation carrier ‘low exercisers’ (SUVR: 
2·36 ± 0·19; F = 8·20, p = 0·006, FDR-adjusted p = 0.018).  
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Previous studies have reported an effect of the APOE ɛ4 allele on the relationship between 
exercise and brain amyloid in LOAD; thus, we re-ran the linear models including APOE ɛ4 
carriage as a covariate and an exercise*APOE ɛ4 interaction. Neither the APOE ɛ4 carriage 
variable, nor the interaction term was a significant predictor of brain amyloid in the mutation 
non-carriers, mutation carrier PiB+ and mutation carrier PiB- groups (data not reported). 
Effect of exercise*EYO interaction on PiB SUVR, CSF Aβ42 and CSF tau 
On examination of the mutation carrier group as a whole, there was no significant effect of the 
exercise group*EYO interaction on PiB SUVR (F = 3·32, p = 0·07), CSF Aβ42 (F = 0·04, p = 
0·85) and CSF tau levels (F = 0·25, p = 0·61; Table 3). After stratification of the mutation 
carrier group by PiB positivity, an interaction was observed between exercise group*EYO on 
PiB SUVR in the PiB+ group (F = 7·04, p = 0·01, FDR-adjusted p = 0.03; Table 4, Figure 2), 
indicative of a stronger association between brain amyloid and EYO in the low exercisers, 
compared to the high exercisers. No effect of the exercise*EYO interaction was noted on levels 





Previous studies of cognitively healthy older adults have established a link between higher 
physical activity levels and lower levels of AD biomarkers (through PET imaging and CSF 
biomarker analysis). This study reports, for the first time, an association between higher 
exercise levels and lower brain amyloid in individuals who have already accumulated high 
levels of brain amyloid and are carriers of mutations in APP, PSEN1 or PSEN2 genes, which 
are known to cause AD with full penetrance. More specifically, we observed mutation carriers 
reporting less than 150 minutes of exercise per week had a higher mean level of brain amyloid, 
compared with those reporting 150 or more minutes of exercise per week. Furthermore, we 
report a significant interaction of exercise group*EYO on amyloid load, whereby in PiB+ 
mutation carrier low exercisers the relationship between brain amyloid and EYO was more 
marked, compared with high exercisers (Figure 2). 
High levels of physical activity have been previously associated with lower brain amyloid 
levels in cognitively healthy older adults at increased risk of late onset Alzheimer’s disease, 
due to carriage of a major genetic risk factor (APOE ε4 carriage) [17, 18]. Consequently, we 
hypothesised that exercise may also positively influence individuals carrying mutations for 
ADAD through a reduction in brain Aβ and/or slowed Aβ accumulation. Within the current 
study, in a cohort of individuals with ADAD genetic mutations who were also dichotomized 
as PiB positive (i.e. in whom significant levels of aggregated Aβ are already present in the 
brain), we observed significantly lower levels of cortical amyloid consistent with high levels 
of exercise. We also observed a significant effect of the interaction term exercise group*EYO 
on brain amyloid. Our results indicate that in PiB+ low exercisers, the expected strong 
association between brain amyloid load and EYO exists [2]. Conversely, and importantly, we 
observed no association between brain amyloid and EYO in the PiB+ high exercisers, which is 
not the expected course of the disease for individuals with ADAD mutations. Our findings may 
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reflect the notion that low exercisers are more likely to follow the usual disease course of 
ADAD (i.e. increasing amyloid accumulation with increasing EYO), than high exercisers. 
Although our findings are novel and promising, the cross-sectional study design does not allow 
causal inferences. In order to further examine the relationship between exercise and the 
trajectory of amyloid accumulation, and subsequent symptom onset in individuals with ADAD 
mutations, longitudinal analyses of the impact of exercise habits on disease course are vital. 
 
The reported association between exercise and brain amyloid levels was limited to participants 
who were mutation carriers and PiB positive (i.e. in those with significant pathology present, 
at levels comparable to a positive PiB scan in sporadic AD). It is possible, however, that the 
low variability in PiB SUVR levels in those deemed PiB negative may account for the lack of 
findings in this group. Bateman et al. [2] showed Aβ deposition in ADAD mutation carriers 
begins approximately 20 years before the onset of clinical symptoms. Should exercise be 
effective in delaying Aβ accumulation, it would be reasonable to assume that this mechanism 
of action would also be vital in the early stages of neuropathological changes (i.e. those who 
are PiB-). Thus the lack of association in this study between exercise and brain Aβ in the PiB- 
group is unexpected. To further understand this relationship, a longitudinal study evaluating 
exercise levels and brain Aβ over long periods (i.e. from -15 EYO until 0 EYO) is necessary.  
In contrast to the observed association between exercise and brain amyloid levels (quantified 
by PiB PET), we did not observe an association between exercise and CSF levels of Aβ42, or 
tau, in the mutation carriers. It is possible that exercise plays a role in reducing the deposition 
of soluble Aβ into cerebral amyloid plaques, rather than modulating the production of soluble 
Aβ (levels of which are quantified by the CSF assays). Recent studies have reported a close 
association between changes in CSF Aβ42 and brain amyloid in the earliest stages of AD 
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pathology.[26] Nevertheless, CSF Aβ42 levels and brain amyloid levels appear to diverge once 
significant plaque load is present; which may explain the lack of association between CSF Aβ42 
and exercise levels in the PiB+ group. The use of amyloid brain imaging may provide a more 
robust measurement for the evaluation of the relationship between exercise and aggregation of 
Aβ into amyloid plaques. However, due to the vast literature supporting the use of CSF Aβ42 
and tau as biomarkers of AD [27], these measurements should be considered in future 
longitudinal studies of exercise and AD biomarkers. 
We report an association between exercise levels and brain amyloid in those with genetic 
mutations known to cause increased Aβ; nevertheless, whether exercise is associated with 
reduced Aβ deposition, or enhanced Aβ clearance remains to be established. Aβ is produced 
from the amyloid precursor protein (APP), which is cleaved via one of two competing 
pathways: the non-amyloidogenic pathway and the amyloidogenic pathway [28]. Evidence 
from animal studies indicates exercise may contribute to both the alteration of APP processing 
towards the non-amyloidogenic pathway resulting in reduced Aβ production, and to 
improvement of Aβ clearance in the brain. Indeed, decreased levels of APP cleavage fragments 
(αCTFs and βCTFs), but not levels of APP itself, have been observed in exercising AD 
transgenic mice, suggesting increased non-amyloidogenic processing [9, 11]. Furthermore, 
exercise-induced increases in activity of neprilysin and insulin degrading enzyme, both known 
Aβ proteases, indicates a positive effect of exercise on Aβ degradation [29, 30]. It is possible 
that through the conduct of both longitudinal studies and well-designed exercise intervention 
trials, we may have the opportunity to establish whether exercise contributes to decreased Aβ 
deposition or enhanced clearance (or possibly both), in this unique cohort of individuals 
carrying ADAD genetic mutations. 
To our knowledge, this preliminary study is the first report of an association between exercise 
level and brain amyloid in a cohort of pre-symptomatic ADAD mutation carriers. Nevertheless, 
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this study is not without limitations. As stated earlier, this is a cross-sectional analysis, and thus 
the direction of the reported associations cannot be inferred. Although it is possible that low 
exercise might be an early symptom of amyloid accumulation, the association between exercise 
and amyloid remained stable following adjustment for EYO (i.e. years from expected symptom 
onset). A more likely hypothesis is that higher exercise alters amyloid accumulation, which is 
supported by previous animal work; however, this hypothesis requires further investigation 
using longitudinal and intervention trial designs. Furthermore, we utilised an exercise 
questionnaire specifically designed for this study (i.e. not previously validated) and also 
acknowledge that the reported exercise levels are higher than that of the wider community. 
Nevertheless, it is likely that our cohort is highly motivated to participate in exercise, given the 
increasing literature linking a healthy lifestyle (including exercise) to reduced biomarkers of 
Alzheimer’s disease, and enhanced overall cognitive health. Coupled with corroboration of 
reports by a collateral source and truncation of exceptionally high reports, we believe the 
reports of exercise are a relatively true representation in this unique genetic group. It is 
important to note that we only quantified the duration of exercise undertaken by participants. 
Future studies should evaluate intensity, frequency, duration and type of exercise and physical 
activities, in an attempt to identify the optimum exercise/physical activity regimen, in terms of 
modulating Alzheimer’s disease biomarkers. We attempted to control for factors which may 
confound the relationship between exercise and AD pathology, including EYO, age and APOE 
ɛ4 allele carriage. Nonetheless, we were limited by small sample size which thus requires 
limited inclusion of additional variables of interest in the model. Importantly, exercise may be 
a proxy for other healthy lifestyle decisions and behaviours, including dietary habits, midlife 
obesity, body mass index, and tobacco abuse, among other potential modifiable risk factors 
shown to modify AD risk and pathology in non-ADAD cohorts. 
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To our knowledge, this study is the first to demonstrate an association between high levels of 
exercise and lower brain amyloid as a function of expected years from symptoms onset in those 
known to have ADAD genetic mutations and in whom high levels of brain amyloid are already 
present. These findings support previous work conducted in cognitively healthy older adults; 
however, the relationship between brain amyloid and exercise in ADAD mutation carriers 
requires further confirmation. Future research should include longitudinal studies of exercise 
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Table 1. Demographic and clinical cohort characteristics stratified by non- carriers and 
carriers of autosomal dominant Alzheimer’s disease mutations, split by exercise level. 
 NC Low 
exercise 
(n = 37) 
NC High 
Exercise 









(n = 33) 
MC High 
exercise 







Age, y 39·2 ± 11·6 39·0 ± 11·3 0·94 38·6 ± 7·9 33·7 ± 9·3 0·008 
EYO N/A N/A N/A -10·2 ± 9·4 -13·6 ± 9·2 0·07 
Years of Education 15·0 ± 3·2 14·9 ± 2·5 0·89 14·9 ± 2·8 14·7 ± 2·8 0·66 
Gender, Female % (n) 65 (24) 56 (57) 0·37 64 (21) 56 (59) 0·42 
APOE ɛ4 allele carriers, 
% (n) 
21.6 (8) 30.7 (31) 0.29 36.4 (12) 25.7 (27) 0.24 
PiB SUVR 1·03 ± 0·08 1·05 ± 0·07 0·21 1·77 ± 1·03 1·59 ± 0·64 0·23 
PiB+** ,% (n)  0 (0) 0 (0) N/A 49 (16) 52 (55) 0·73 
GDS 1·4 ± 1·7 1·3 ± 1·6 0·66 2·2 ± 2·2 1·4 ± 1·8 0·04 
BMI, kg/m2 29·3 ± 8·7  29·4 ± 9·8 0·96 29·8 ± 9·6 27·2 ± 6·2 0·07 
High cholesterol, % (n) 11 (4) 17 (17) 0·54 21 (7) 12 (13) 0·24 
Hypertension, % (n) 13 (5) 18 (18) 0·82 12 (4) 5 (5) 0·13 
Exercise duration/week, 
minutes 
68 ± 43 427 ± 218 <0.001 64 ± 51 522 ± 343 <0.001 
Mutation carriers, n,  
APP/PSEN1/PSEN2 
N/A N/A N/A 17 / 7 / 9 85 / 9 / 12  
Unless otherwise described, data are presented as mean ± standard deviation of the mean 
*From independent samples t-test for continuous variables and chi-square for categorical 
variables. **Those with PiB SUVR 1·3 and greater were categorised as PiB positive (PiB+). 
Abbreviations: APOE, Apolipoprotein E; APP, amyloid precursor protein; BMI, body mass 
index; EYO, estimated years from expected symptom onset; GDS, Geriatric Depression 
Scale; kg/m2, kilograms per metre squared;  MC, Mutation Carriers; NC, Mutation Non-
Carriers; y, years; PiB SUVR, Pittsburgh Compound B standardised uptake value ratio; 
PSEN1, Presenilin 1; PSEN2, Presenilin 2.  
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Table 2. Mutation non-carriers: Results from linear models, examining the differences in Pittsburgh Compound B positron emission tomography 
(PiB PET) measured brain amyloid burden and CSF biomarkers between the low and high exercise groups (models also included family mutation, 
EYO, age, and an EYO*exercise interaction). 





Mean (SE) Ɨ 
High 
exercise 
Mean (SE) Ɨ 
F p ηp2  F p ηp2 F p ηp2 F p ηp2 F p ηp2 
PiB SUVR 
(n = 138) 
1.03 (0.01) 1.04 (0.01) 0.33 0.60 0.003 1.53 0.22 0.023 2.64 0.11 0.020 1.71 0.19 0.013 0.43 0.51 0.003 
CSF Aβ42 (ng/L) 
(n = 111) 
387.2 (29.1) 439.6 (18.0) 1.48 0.23 0.014 1.13 0.33 0.021 0.65 0.42 0.006 2.74 0.10 0.026 0.01 0.97 0.001 
CSF tau (ng/L) 
(n = 113) 
53.0 (4.8) 60.4 (3.0) 2.26 0.14 0.021 1.40 0.25 0.026 2.78 0.10 0.026 0.04 0.84 0.001 0.64 0.43 0.006 
*Low exercisers reported less than 150 minutes per week of exercise, high exercisers reported 150 or more minutes of exercise per week. **For 
consistency with the mutation carrier models (Tables 3 and 4), EYO and family mutation were entered into the mutation non-carrier models. 
***The age variable was residualized from EYO. ƗAdjusted marginal means (standard error). Abbreviations: CSF, cerebrospinal fluid; EYO, 
estimated years from expected symptom onset; ng/L, nanograms per litre; PiB SUVR, Pittsburgh Compound B standardised uptake value ratio; 




Table 3. Mutation carriers: Results from linear models, examining the differences in Pittsburgh Compound B positron emission tomography (PiB 
PET) measured brain amyloid burden and CSF biomarkers between the low and high exercise groups (models also included family mutation, 
EYO, age, and an EYO*exercise interaction). 





Mean (SE) Ɨ 
High 
exercise 
Mean (SE) Ɨ 
F p ηp2  F p ηp2 F p ηp2 F p ηp2 F p ηp2 
PiB SUVR 
(n = 139) 
1.59 (0.12) 1.58 (0.09) 2.68 0.10 0.020 2.42 0.09 0.035 41.30 <0.001 0.238 1.86 0.17 0.014 3.32 0.07 0.025 
CSF Aβ42 (ng/L) 
(n = 120) 
337.5 (30.7) 349.1 (22.9) 0.01 0.95 0.001 1.54 0.22 0.026 21.05 <0.001 0.157 0.01 0.99 0.001 0.04 0.85 0.001 
CSF tau (ng/L) 
(n = 121) 
81.0 (9.4) 82.1 (6.9) 0.25 0.62 0.002 0.85 0.43 0.015 13.4 <0.001 0.105 0.14 0.71 0.001 0.25 0.61 0.002 
*Low exercisers reported less than 150 minutes per week of exercise, high exercisers reported 150 or more minutes of exercise per week. **The 
age variable was residualized from EYO. ƗAdjusted marginal means (standard error). Abbreviations: CSF, cerebrospinal fluid; EYO, estimated 





Table 4. Mutation carriers stratified by brain amyloid load: Results from linear models, examining the differences in Pittsburgh Compound B 
positron emission tomography (PiB PET) measured brain amyloid burden and CSF biomarkers between the low and high exercise groups, 
following stratification of the mutations carriers by PiB PET SUVR status (models also included family mutation, EYO, age, and an EYO*exercise 
interaction). 
  Exercise* Family Mutation EYO Age** EYO*Exercise 
  Low 
exercise 
Mean (SE) Ɨ 
High 
exercise 
Mean (SE) Ɨ 
F p ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 
 
PiB SUVR 
MC PiB –  
(n = 68) 
1.09 (0.03) 1.11 (0.02) 1.16 0.28 0.019 0.30 0.74 0.010 2.27 0.14 0.036 0.97 0.33 0.016 0.48 0.49 0.008 
MC PiB + 
(n = 71)  




MC PiB – 
(n = 57)  
387.0 (47.3) 427.8 (31.3) 0.15 0.70 0.003 3.02 0.06 0.108 1.27 0.26 0.025 0.47 0.50 0.009 0.00 0.99 0.001 
MC PiB + 
(n = 63)  




MC PiB – 
(n = 57)  
57.5 (8.6) 64.1 (5.7) 0.01 0.98 0.001 0.30 0.74 0.012 1.03 0.31 0.020 0.15 0.70 0.003 0.16 0.69 0.003 
MC PiB + 
(n = 64)  
109.9 (16.1) 94.3 (13.4) 0.51 0.48 0.009 1.16 0.32 0.039 2.22 0.14 0.037 1.16 0.29 0.020 3.16 0.08 0.052 
*Low exercisers reported less than 150 minutes per week of exercise, high exercisers reported 150 or more minutes of exercise per week. **The 
age variable was residualized from EYO. ƗAdjusted marginal means (standard error). ap-value remained significant (p < 0.05) after false discovery 
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rate correction. Abbreviations: CSF, cerebrospinal fluid; EYO, estimated years from expected symptom onset; MC, mutation carriers; ng/L, 
nanograms per litre; PiB SUVR, Pittsburgh Compound B standardised uptake value ratio; PiB -, PiB negative with an SUVR of less than 1·3; PiB 








Figure 1. Flow diagram indicating number of participants with data available for inclusion in this study. PiB -, PiB negative with an SUVR of less 
than 1·3; PiB +, PiB positive with an SUVR of 1·3 or higher. Low exercisers reported less than 150 minutes per week of exercise, high exercisers 
reported 150 or more minutes of exercise per week. Abbreviations: DIAN, Dominantly Inherited Alzheimer Network study; CDR, Clinical Dementia 







Figure 2. The association between brain amyloid and EYO is more marked in low 
exercisers, compared with high exercisers. PiB positive (PiB+, i.e. those with an SUVR ≥ 
1·3) mutation carriers (MC) reporting less than 150 minutes of exercise per week (low 
exercise) have a more marked association between estimated years from expected symptom 
onset and Pittsburgh Compound B positron emission tomography (PiB PET) standardised 
uptake value ratio (SUVR), compared with PiB+ mutation carriers reporting more than 150 
minutes of exercise per week (high exercise). 
  
 
                 PiB+ MC Low exercise 







1. Ittner, L.M. and J. Gotz, Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. 
Nat Rev Neurosci, 2011. 12(2): p. 65-72. 
2. Bateman, R.J., et al., Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's 
Disease. N Engl J Med, 2012. 
3. Villemagne, V.L., et al., Amyloid beta deposition, neurodegeneration, and cognitive decline in 
sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol, 2013. 12(4): p. 357-
67. 
4. Buchman, A.S., et al., Total daily physical activity and the risk of AD and cognitive decline in 
older adults. Neurology, 2012. 78(17): p. 1323-9. 
5. Rovio, S., et al., Leisure-time physical activity at midlife and the risk of dementia and 
Alzheimer's disease. Lancet Neurol, 2005. 4(11): p. 705-11. 
6. Abbott, R.D., et al., Walking and dementia in physically capable elderly men. JAMA, 2004. 
292(12): p. 1447-53. 
7. Scarmeas, N., et al., Physical activity, diet, and risk of Alzheimer disease. JAMA, 2009. 302(6): 
p. 627-37. 
8. Scarmeas, N., et al., Physical activity and Alzheimer disease course. Am J Geriatr Psychiatry, 
2011. 19(5): p. 471-81. 
9. Adlard, P.A., et al., Voluntary exercise decreases amyloid load in a transgenic model of 
Alzheimer's disease. J Neurosci, 2005. 25(17): p. 4217-21. 
10. Um, H.S., et al., Exercise training acts as a therapeutic strategy for reduction of the 
pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol 
Med, 2008. 22(4): p. 529-39. 
11. Liu, H.L., et al., Long-term treadmill exercise inhibits the progression of Alzheimer's disease-
like neuropathology in the hippocampus of APP/PS1 transgenic mice. Behav Brain Res, 2013. 
256: p. 261-72. 
12. Yuede, C.M., et al., Effects of voluntary and forced exercise on plaque deposition, 
hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. 
Neurobiol Dis, 2009. 35(3): p. 426-32. 
13. Nichol, K.E., et al., Exercise alters the immune profile in Tg2576 Alzheimer mice toward a 
response coincident with improved cognitive performance and decreased amyloid. J 
Neuroinflammation, 2008. 5: p. 13. 
14. Zhao, G., et al., Treadmill exercise enhances synaptic plasticity, but does not alter beta-
amyloid deposition in hippocampi of aged APP/PS1 transgenic mice. Neuroscience, 2015. 
298: p. 357-66. 
15. Moore, K.M., et al., A spectrum of exercise training reduces soluble Abeta in a dose-
dependent manner in a mouse model of Alzheimer's disease. Neurobiol Dis, 2016. 85: p. 218-
24. 
16. Liang, K.Y., et al., Exercise and Alzheimer's disease biomarkers in cognitively normal older 
adults. Ann Neurol, 2010. 68(3): p. 311-8. 
17. Head, D., et al., Exercise Engagement as a Moderator of the Effects of APOE Genotype on 
Amyloid Deposition. Arch Neurol, 2012. 
18. Brown, B.M., et al., Physical activity and amyloid-beta plasma and brain levels: results from 
the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry, 2013. 
18(8): p. 875-81. 
19. Benzinger, T.L., et al., Regional variability of imaging biomarkers in autosomal dominant 
Alzheimer's disease. Proc Natl Acad Sci U S A, 2013. 110(47): p. E4502-9. 
29 
 
20. Su, Y., et al., Partial volume correction in quantitative amyloid imaging. Neuroimage, 2015. 
107: p. 55-64. 
21. Craig, C.L., et al., International physical activity questionnaire: 12-country reliability and 
validity. Med Sci Sports Exerc, 2003. 35(8): p. 1381-95. 
22. World Health Organisation, Global Recommendations on Physical Activity for Health. 2010. 
23. Garber, C.E., et al., American College of Sports Medicine position stand. Quantity and quality 
of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and 
neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci 
Sports Exerc, 2011. 43(7): p. 1334-59. 
24. Benjamini, Y., Yekutieli, D, The control of the false discovery rate in multiple testing under 
dependency. The Annals of Statistics, 2001. 29(4): p. 1165-1188. 
25. Tabachnick, B.G. and L.S. Fidell, Using multivariate statistics. 5th Edition ed. 2007, Needham 
Heights, MA, USA: Pearson Education. 
26. Vlassenko, A.G., et al., Imaging and cerebrospinal fluid biomarkers in early preclinical 
alzheimer disease. Ann Neurol, 2016. 80(3): p. 379-87. 
27. Fagan, A.M., et al., Longitudinal change in CSF biomarkers in autosomal-dominant 
Alzheimer's disease. Sci Transl Med, 2014. 6(226): p. 226ra30. 
28. Verdile, G., et al., The role of beta amyloid in Alzheimer's disease: still a cause of everything 
or the only one who got caught? Pharmacol Res, 2004. 50(4): p. 397-409. 
29. Lazarov, O., et al., Environmental enrichment reduces Abeta levels and amyloid deposition in 
transgenic mice. Cell, 2005. 120(5): p. 701-13. 
30. Tabuchi, M., et al., Sleep interacts with abeta to modulate intrinsic neuronal excitability. Curr 
Biol, 2015. 25(6): p. 702-12. 
 
